Decay-Accelerating Factor Suppresses Complement C3 Activation and Retards Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice by Leung, VWY et al.
 1 
Decay-Accelerating Factor suppresses Complement C3 activation 
and retards Atherosclerosis in Low Density Lipoprotein Receptor 
Deficient Mice 
Short title:  DAF protects from atherosclerosis 
Viola WY Leung 1, 2† 
Sheng Yun 1† 
Marina Botto3 
Justin C Mason 1 
Talat H Malik 3 
Wenchao Song 4 
Danielle Paixao-Cavalcante3 
Matthew C Pickering 3 
Joseph J Boyle 1,2 
Dorian O Haskard 1* 
Vascular Science Section, National Heart and Lung Institute1, Division of Investigative 
Sciences2 and the Molecular Genetics and Rheumatology Section, Division of Medicine 3, 
Imperial College London, Hammersmith Hospital, London, UK; University of 
Pennsylvania, Philadephia, USA 4.†   SY and VWYL are joint first authors 
* Corresponding author: Professor Dorian O. Haskard,  Vascular Science Section, 
Imperial College, Hammersmith Hospital, Du Cane Road,  London W12 0NN, UK; 
Tel: +44 (0) 208 383 3064; Email: d.haskard@imperial.ac.uk    
This work was funded by the British Heart Foundation. The authors have no conflicts 
of interest. 
Number of Text Pages:  34;  Figures: 7;  Tables: 1  
 2 
ABSTRACT   
Objective: Decay-accelerating factor (CD55) is a membrane protein that regulates 
complement pathway activity at the level of C3. We tested the hypothesis that DAF 
plays an essential role in limiting complement activation in the arterial wall and 
protecting from atherosclerosis. 
Methods and Results: DAF gene targeted mice (daf-1-/-) mice were crossed with 
LDL-receptor deficient (Ldlr-/-) mice. Daf-1-/-Ldlr-/- mice had more extensive en face 
Sudan IV staining of the thoracoabdominal aorta than Ldlr-/- mice, both following a 
12-week period of low fat diet (4.66 + 0.63 %  vs  2.85 + 0.34 %, mean + SEM, 
p<0.03), or a high fat diet  (11.82  +  0.89 %  vs  Ldlr-/- 8.11  + 1.04 %, p<0.03).  
Aortic root lesions in daf-1-/-Ldlr-/- mice on a low fat diet showed increased size and 
complexity. DAF deficiency increased deposition of C3d and C5b-9, indicating the 
importance of DAF for downstream complement regulation in the arterial wall. 
Conclusion: The acceleration of lesion development in the absence of DAF provides 
confirmation of the proinflammatory and proatherosclerotic potential of complement 
activation in the Ldlr-/- mouse model. Since upstream complement activation is 
potentially protective, this study underlines the importance of DAF in shielding the 
arterial wall from the atherogenic effects of complement.   
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INTRODUCTION 
Complement, a complex cascade of serine proteases, is well characterised as playing a 
pivotal role in inflammation, and in bridging innate and adaptive immunity (1). In 
current understanding, complement is triggered by three proximal cascades, the 
classical, alternative and mannose-binding lectin pathways, which converge on C3 at 
the central hub of the system. Cleavage of C3 leads to the generation of down-stream 
proinflammatory mediators, including the anaphylatoxins C3a and C5a and the 
membrane attack-complex C5b-9.  Whilst the assembly and insertion of C5b-9 into 
cell membranes may lyse non-nucleated cells, sublytic levels can activate 
proliferation and/or proinflammatory gene expression (2).   
 
There is increasing interest in dissecting the possible roles of complement in 
atherosclerosis in vivo (3;4). Theoretically, many factors might activate complement 
in the arterial wall, including  immunoglobulins, cholesterol crystals, enzymatically-
modified LDL and apoptotic cells (5-12). However enzymatically-modified LDL is 
likely to be the most abundant stimulus for complement activation in atherosclerosis, 
and may act via the alternative pathway and also via direct binding of C1q and C-
reactive protein (CRP) (8;9;13-15). In addition, the classical and alternative pathways 
are capable of low grade “tick-over” activity (16;17).  
 
Previous experimental work has focused on the effects of natural or experimental 
deficiency of individual complement pathway components. Relevant studies are as 
follows: (i) rabbits with natural deficiency of C6 have been shown to be protected 
from diet-induced atherosclerosis (18;19); (ii) although C5 deficiency has been found 
to have no effect on lesion development in high fat diet-fed ApoE-/- mice (20), a recent 
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study has shown protective effects of an anti-C5 antibody in ApoE-/- mice deficient in 
both Cd59a and Cd59b genes (21);  (iii) C3 deficient mice crossed with Ldlr-/- single 
knock-out mice have been found to have increased aortic lipid deposition with 
impaired lesion development beyond the foam cell stage (22); (iv) crossing Factor B 
deficient mice with ApoE-/-Ldlr-/- double-knock-outs had no effect, arguing against an 
important role for the alternative pathway in that model (23); and (v) more recently, 
we have reported that low fat diet-fed Ldlr-/- mice deficient in classical pathway 
activity through gene-targeting of C1q (C1qa-/-) show accelerated atherosclerosis with 
increased lesion complexity (24). The increased lesion size and complexity in low fat 
diet-fed C1qa-/-Ldlr-/- mice was associated with an increase in lesional apoptotic cells, 
consistent with previous studies which have demonstrated a direct role for C1q in 
apoptotic cell clearance, independent of terminal pathway activation (25;26). Recently 
the role of the lectin pathway has also been shown to have atheroprotective functions 
in mice  (27), in line with the involvement of mannose-binding lectin in apoptotic cell 
clearance and also with the association of mannose-binding lectin deficiency with 
accelerated atherosclerosis in humans (28;29). 
 
Complement activity is tightly regulated by a number of fluid-phase and membrane-
bound inhibitors, including the two glycosylphosphatidylinositol (GPI)-anchored 
membrane proteins decay-accelerating factor (DAF, CD55) and protectin (CD59). 
Whereas CD59 inhibits insertion of C9 into cell membranes and thus the development 
of C5b-9 membrane attack complexes, DAF binds to C3, thereby accelerating the 
decay of the two C3 convertases, C3Bb (alternative pathway) and C4b2a (classical 
and mannose-binding lectin pathways) (30-32). Structurally, DAF is a multidomain 
protein comprising a proximal serine/threonine-rich region and four complement 
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control protein (CCP) domains, of which CCP2 and CCP3 dissociate C3Bb and 
C4b2a oligomers into constituent proteins. The catalytic mechanism of DAF activity 
is not fully clear, but the crystal structure and substitution mutants identify Bb 
(Tyr338), DAF-CCP2 (Arg69, Arg96) and DAF-CCP3 (Phe148 Leu171) as key 
residues (33;34).   
 
The mouse has two DAF genes encoding GPI-anchored and trans-membrane forms 
respectively, with the former being more representative of human DAF (35). Gene-
targeting of the GPI-anchored form has led to the generation of a knock-out strain that 
is healthy but shows exaggerated inflammation in models of renal,  autoimmune and 
nervous system diseases (36-39). Recently no protection or exacerbation of 
atherosclerosis was observed after crossing these mice with the ApoE-/- strain  (40). 
 
Observations that the classical pathway exerts atheroprotective effects without 
terminal pathway activation suggest the importance of a strong complement 
regulatory system in the arterial wall (14;24).  Consistent with this, we and others 
have recently published evidence that CD59 deficiency leads to an acceleration of 
atherosclerosis in Ldlr-/- and ApoE-/- mouse models, establishing the proatherogenic 
potential of the terminal complement pathway and highlighting the importance of 
CD59 in its regulation (21;40;41). We show in this paper that DAF also plays a role in 
the regulation of atherosclerosis in the Ldlr-/- model. 
 
MATERIAL AND METHODS 
Reagents: Oil Red O (ceristain grade), dextrin, gelatin, Mayer’s Haematoxylin, L-
glutamic acid, glycerol, sodium azide, calcium chloride, magnesium sulphate and 
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sodium phosphate were obtained from Merck Biosciences/BDH, Poole, UK.  
Buffered formal saline (4% w/w formaldehyde solution) was from Pioneer Research 
Chemicals, Colchester, Essex.  OCT compound was from CellPath, Newtown, Powys, 
UK.  Other reagents were from Sigma-Aldrich, Poole, UK. 
 
Antibodies: Primary antibodies included rat anti-mouse macrophages/monocyte 
MOMA-2 (Serotec, Oxford, UK), alkaline phosphatase-conjugated mouse anti-alpha 
actin (clone α1A4) (Sigma-Aldrich, Poole, UK), rat monoclonal anti-mouse DAF 
(clone MD1, a kind gift from Prof BP Morgan, Cardiff, UK), goat anti-mouse IgM 
(Abcam, Cambridge, UK), and rabbit anti-C5b-9 (Cat. # 204903, Calbiochem, Merck 
Biosciences, Darmstadt, Germany). Secondary antibodies were biotinylated goat anti-
rabbit IgG (DakoCytomation, Cambridgeshire, UK), biotinylated goat anti-mouse IgG 
(Dako, Ely, UK). Control antibodies were fluorescein-conjugated goat IgG (Santa 
Cruz Biotechnology, Inc., Heidelberg, Germany), biotinylated goat IgG (R&D 
Systems, UK), and anti-NFκB p65, biotin-conjugated anti-GFP, rabbit anti-
vitronectin, and polyclonal rabbit anti-clusterin (all from Santa Cruz Biotechnology, 
Inc., Heidelberg, Germany).   
 
Mice: DAF gene-targeted mice (daf-1-/-) were generated as described (36). Ldlr-/- mice 
were obtained from Jackson Laboratories (Bar Harbor, Maine, USA). Both daf-1-/- 
and Ldlr-/- mice were back-crossed for 10 generations on to the C57BL/6 background 
prior to intercrossing to form daf-1-/-Ldlr-/- double knockout mice. DAF  genotypes 
were determined by polymerase chain reaction. C3 deficient Ldlr-/- (C3-/-Ldlr-/-) mice 
were made by crossing Ldlr-/- mice with a C3 gene-targeted strain (42). All mice in 
the study were female. Animals were housed in a specific pathogen-free environment 
and studied according to UK Home Office regulations. The experimental groups were 
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gradually transferred onto low fat or high fat diets at 10 weeks of age, as described 
(41). All mice were studied at 22 weeks of age. 
 
Lipoprotein, cholesterol and triglyceride analysis: Blood was withdrawn from the 
inferior vena cava after sacrifice and allowed to clot on ice.  Serum was kept at 4oC 
for up to 24 hours before analysis. Lipoprotein profiles were analyzed on pooled sera 
by size-exclusion chromatography using a SMARTTM micro-FPLC system 
(Pharmacia, Sweden). Serum total cholesterol and triglycerides were measured 
enzymatically on each individual mouse using Kit Infinity TR13421/2350-250 and 
Kit Infinity TR22421/2780-250 respectively (MediMark, Grenoble, France) according 
to the manufacturer’s instructions.     
 
Quantification and immunohistochemistry of atherosclerotic lesions: Mice were killed 
by exsanguinations under carbon dioxide (CO2).  En face staining of 
thoracoabdominal aorta and quantification of the aortic root lesion area were 
conducted as described (24;41). Immunohistochemistry was performed by standard 
procedures on residual sections not required for analysis of lesion size, as described 
(24;41).  Results of immunocytochemistry are presented as a percentage area fraction 
of the aortic root or as the percentage of lesional cells, as analysed by Image ProPlus 
TM
 software above.   
 
Confocal microscopy imaging: Cryosections were incubated with combinations of 
markers including: Cy3-labelled anti-alpha actin (clone α1A4) (Sigma-Aldrich, 
Poole, UK); AlexaFluor® 488-conjugated CD31 (Clone MEC13.3; BioLegend Inc., 
San Diego, USA), AlexaFluor® 568-labelled anti-CD68 (MCA1957A488, Serotec, 
Oxford, UK); fluorescein-conjugated goat IgG fraction to mouse complement C3 (Cat 
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# 555000, MP Biomedicals, Solon, Ohio, USA); biotinylated anti-mouse complement 
3d (R&D Systems, Abingdon, UK), fluorescein-streptavidin (Vector Laboratories, 
Peterborough, UK) and rat anti-mouse DAF (clone MD1) followed by biotinylated 
polyclonal rabbit anti-rat secondary and development with AlexaFluor® 488- or 
AlexaFluor® 568-conjugated streptavidin (Invitrogen, Paisley, UK). Nuclei in 
fluorescence sections were then counterstained with TOPRO-3 before mounting in 
80% glycerol 20% PBS. Sections were examined by confocal or by standard 
fluorescence microscopy (for enumerating % actin-positive cells and fibrous caps).  
The confocal used was a Zeiss LSM510 Meta using a standard trichannel set up using 
the Ar 488nm line, the HeNe 543nm line and the HeNe 633nm line, a 1 Airy Unit 
pinhole (adjusted for light wavelength) and 3 photomultipliers fed via green (505-
530nm BP), orange-red (560-615nm BP) and far red (LP638nm) filters. As advised by 
Zeiss, photomultiplier (PMT) voltages and amplifier offset were adjusted online using 
fast scan to maximise image clarity without saturation, and gain was left at the 
manufacturer’s default.  PMT voltages were typically green emission 600V, orange-
red emission 400V, and far red emission 200V.  
 
Collagen content in atherosclerotic lesion: Aortic root sections were stained with 1% 
Sirius red in saturated picric acid (Picrosirius Red) for an hour, as described  We 
adopted as closely as possible the methods of the laboratories of Libby and Hansson 
(43). Polarising microscopy was used to view these sections at x4 magnification 
(Olymus BX50).  Images were then captured with Olympus DP50 digital microscopy 
camera. Thin collagen fibres (green) and thick collagen fibers (orange/red) were 
measured using NIH open access generic image analysis software Image J 
(http://rsbweb.nih.gov/ij (24)). Images were first converted into three greyscale 
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images (red, green and blue).  For red and green channels, lesions in each aortic root 
section were carefully drawn.  After intensity thresholding each image, we measured 
the area fraction of threshold collagen (the relative amount of collagen area to 
selected lesion area) within each aortic root lesion, and expressed this as a percentage. 
 
ELISA for detection of mouse C3: ELISA plates were coated overnight with goat 
anti-mouse C3 (2mg/ml; MP Biomedicals, OH, USA), which also reacts with C3b, or 
with goat anti-mouse C3d (2mg/ml; R&D system, MN, USA). After blocking, the 
plates were incubated with wild-type, factor I-deficient or trypsin-treated wild-type 
sera as a source of intact C3, C3b and C3d, respectively. Bound C3 was detected by 
adding biotinylated goat anti-mouse C3d (50ng/ml) or biotinylated goat anti-mouse 
C3 (50ng/ml). Plates were incubated with streptavidin-AP conjugated and the reaction 
visualized by subsequent addition of p-nitrophenyl phosphate substrate (Sigma Fast 
TM
, Sigma-Aldrich Co., Gillingham, UK).  
 
C3 immunostaining in renal tissue: Kidney frozen sections from factor-I deficient 
mice were immunostained with FITC-conjugated goat anti-mouse C3 or biotinylated-
goat anti mouse C3d. To confirm the affinity of goat anti-mouse C3d antibody the 
kidney sections from factor-I deficient mice were treated in vitro with sera from mice 
with combined deficiency of factor H and C3 (as source of mouse factor I) for 30 min 
at 37ºC and immunostained.  
 
Quantification of C3 and C3d deposition: Aortic roots were stained to quantify 
expression of both C3 and C3d.  Sections for each cohort were immunostained and 
imaged contemporaneously, and quantified by confocal microscopy (Zeiss 
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LSM510Meta). Green fluorescence staining was quantified by a minor modification 
of published methods (44;45). Using Image J (http://rsbweb.nih.gov/ij), the operator 
split the RGB image file for each section and then measured the intensity in the green 
channel taking care to restrict analysis to the lesion as a region of interest. Within 
each atherosclerotic lesion, we first obtained the area fraction for positive staining by 
measuring the total number of pixels and the fraction of those pixels that were non-
zero.  Using the histogram function on slides stained with the isotype control, a 
threshold was set below which fluorescence was deemed non-specific. Then, for the 
specific positive pixels, we measured the absolute fluorescence intensity (44).  
 
Quantification of C5b-9 deposition: Neoepitopes on C5b-9 were detected with a 
rabbit polyclonal antibody raised against human C5b-9 (Calbiochem, Merck 
Biosciences, Beeston, UK) that has previously been used by us and others to detect 
C5b-9 in mouse tissues (23;39). Aortic root sections were stained with anti-C5b-9 or 
control IgG, followed by biotinylated goat anti-rabbit IgG and the ABC-peroxidase 
system (Dako, Ely, UK), using 3,3'-diaminobenzidine tetrahydrochloride (DAB) as 
substrate.  Anti-C5b-9 staining was scored blind on a 0, + (weak), ++ (moderate) and 
+++ (strong) semi-quantitative scale.    
 
Statistics: Typically values for a given aortic root were the mean of five sections.  
Unless stated otherwise, data are expressed as mean ± standard error of the mean and 
were analysed by two-tailed Student’s t-test. Statistical significance of all tests was 
defined as p<0.05.  
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RESULTS 
 
 
Body weight and serum lipids in daf-1-/-Ldr-/- mice:  The characteristics of the study 
groups are shown in Table I. No major differences were observed between Ldr-/- and 
daf-1-/-Ldr-/- strains in body weight, total serum cholesterol and triglyceride levels.  
Furthermore, there were no differences in the lipoprotein profiles of Ldlr-/- and daf-1-/-
Ldlr-/- mice (not shown).   
 
Effect of DAF deficiency on lesions in en face preparations of thoracoabdominal 
aortae:  Whilst lesions in en face preparations of thoracoabdominal aortae were barely 
detectable at 22 weeks in Ldlr-/- mice fed a low fat diet, DAF deficiency led to 
significant enhancement (daf-1-/-Ldlr-/-  4.66 + 0.63 %  versus  Ldlr-/- 2.85 + 0.34 %, 
mean + SEM, p<0.03).  A high fat diet increased lesion areas in Ldlr-/-  mice 
approximately three-fold, with daf-1-/-Ldlr-/- mice still having significantly larger 
lesions  (daf-1-/-Ldlr-/-  11.82  +  0.89 %  versus  Ldlr-/- 8.11  + 1.04 %, p<0.03) (Figure 
1).   
 
Effect of DAF deficiency on atherosclerotic lesion area: Increased atherosclerotic 
lesion formation in daf-1-/-Ldlr-/- mice fed a low fat diet was also evident in the aortic 
roots, with larger lesions, either when expressed as absolute lesion area (daf-1-/-Ldlr-/- 
76.16 + 9.53 x 103 µm2  vs Ldlr-/- 29.42 + 3.83 x 103 µm2; p<0.001), or as a fraction of 
the aortic root (daf-1 -/-Ldlr-/- 6.72 ± 1.11 % vs  Ldlr-/- 2.64 ± 0.35 %; p < 0.005) 
(Figure 2).  Following a high fat diet, aortic root lesions in Ldlr-/- mice were already so 
large as to be take up around a third of the available lumen, and differences between  
Ldlr-/- and daf-1-/-Ldlr-/- did not reach statistical significance (lesion area fraction in 
daf-1-/-Ldlr-/- 27.73 ± 0.96 % vs Ldlr-/- 22.44 ± 2.32 %, p = 0.051) (Figure 2).    
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Histological analysis of aortic root lesions: Aortic root lesions in low fat diet-fed Ldlr-
/-
 mice were composed almost entirely of macrophages, as detected by mAb Moma-2, 
with poorly developed shoulders. In contrast, DAF-/-Ldlr-/- mice fed a low fat diet had 
lesions that had evolved from fatty streaks (Stary-Class II) to fibrous cap lesions 
(Stary Class IV), as judged by a significant increase in the alpha actin-positive 
vascular smooth muscle cells (VSMC) within lesions, well-defined shoulders and 
lipid cores (Figure 3A-D). Lesions in the aortic roots of Ldlr-/- mice are well known to 
be rupture-resistant, and we did not observe ruptured plaques. Quantification of the 
lesion percentage taken up by VSMC showed an approximately six-fold increase in 
daf-1-/-Ldlr-/- mice (6.72 ± 2.18 % in daf-1-/-Ldlr-/- vs 0.68  ± 0.01 % in Ldlr-/-, p < 
0.002) (Figure 3E). Following a high fat diet, the proportion of macrophages in 
relation to lesional cells dropped (Figure 3F), whilst the number of alpha-actin 
positive cells was significantly increased to approximately 15% of cells, with no 
significant differences between strains. In confirmation of the increased complexity of 
lesions in daf-1-/-Ldlr-/- mice, we observed increased collagen % area fraction of thin 
collagen fibres (green Picrosirius Red staining) in the absence of DAF, both after a 
low fat diet (2.19  ± 0.57 in daf-1-/-Ldlr-/- vs 0.38 ± 0.16 in Ldlr-/- ; p < 0.001) and after 
a high fat diet (7.74  ± 1.41 vs 1.06 ± 0.37; p < 0.0001). Similarly, % area fraction of 
thick collagen fibres (orange-red Picrosirius Red staining) was also increased (4.42  ± 
1.01 vs 3.70 ± 0.88 after a low fat diet (p < 0.001); 10.99  ± 2.11 vs 4.30 ± 1.04  (p < 
0.004) after a high fat diet). We observed diffuse lesional immunostaining of IgM and 
IgG, which was similar between- strains (not shown).  
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Distribution of DAF: Double immunofluorescence confocal staining of arterial tissue 
of Ldlr-/- mice showed clear expression of DAF by endothelial cells and macrophages, 
although DAF expression by endothelium over lesions appeared reduced (Figure 4A-
D).  Furthermore, expression on macrophages appeared stronger on subendothelial 
macrophages than on macrophages nearer the necrotic core (Figure 4E-H).  DAF 
expression by VSMC was weak-absent (Figure 4I-L).  Furthermore, when these 
double-stained sections were considered together, there was no evidence for DAF 
expression within the acellular lipid core of lesions. There was also strong DAF 
staining in the adventitia, but this was not characterised further. No DAF staining was 
detected in aortic roots of daf-1-/-Ldlr-/- mice, verifying the specificity of the rat anti-
mouse DAF mAb MD1 (not shown).   
 
Validation of anti-C3d antibody for use on mouse tissues:  Before using the anti-C3d 
antibody to analyse atherosclerotic lesions, we validated its use for the detection of 
activated C3 in the mouse. First, the anti-C3d antibody failed to react with native C3 
in wild-type plasma using a sandwich ELISA, but reacted with wild-type serum 
activated by trypsin to generate C3d (Figure 5A).  The anti-C3d antibody also failed 
to detect antigen in Factor I deficient serum, in which all circulating C3 has been 
shown by western blotting to be C3b, and in which there is a defect in cleaving C3b to 
iC3b or C3d (Figure 5A) (37). As previously reported (38), Factor I deficient mice 
have readily detectable mesangial deposition of C3b (Figure 5B).  No staining was 
seen with the anti-C3d antibody (Figure 5C), demonstrating that the anti-C3d 
antibody does not react with C3 or C3b in tissue. Following incubation of the sections 
with a source of murine factor I (serum from mice deficient in both C3 and factor H), 
which triggers the physiological cleavage of C3b to iC3b and C3d, mesangial C3 
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reactivity became apparent using both the anti-C3 and anti-C3d antibody (Figure 
5C,D). 
 
Quantification of C3 and C3d deposition: Staining of sections for C3 showed a diffuse 
distribution within lesions in both strains, although on the low fat diet the area of 
staining was slightly greater in DAF deficient mice (p< 0.03) (Figure 6A). The  
intensity of C3 fluorescence staining was increased significantly by the high fat-diet 
in Ldlr-/- mice, and was significantly greater in daf-1-/-Ldlr-/- compared to Ldlr-/- mice 
on either diet (Figure 6B).  Applying the anti-C3d antibody to aortic root sections, 
positive staining was seen diffusely, implying complement activation products in both 
cellular and acellular regions of the plaques (Figure 6E-J). Consistent with 
uncontrolled complement activation, quantitative immunofluorescence of C3d 
confirmed a significant four-fold increase in the area and intensity of staining for C3d 
in daf-1-/-Ldlr-/- on the low fat diet (% of lesion positive for C3d 42.41 + 4.01 % vs 
10.68 + 1.13 %, p < 0.001) and this increase was amplified by the high fat diet (70.78 
+ 3.55 % vs. 22.05 + 6.91 %, p < 0.001) (Figure 6C,D).  Notably, diet made no 
difference to lesional C3d in Ldlr-/- single knock-outs, testifying to the competence of 
C3 regulation in these animals (Figure 6C,D). No C3 or C3d staining was seen in 
lesions of C3 deficient Ldlr-/- mice after a low or high fat diet, establishing specificity 
of staining.  
 
Semi-quantitative analysis of C5b-9 deposition:  Activation of the terminal pathway, 
as judged by deposition of C5b-9, was detected with DAB immunocytochemical 
staining, and assessed on semi-quantitative scale. As shown in Figure 7, C5b-9 
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deposition was significantly greater in daf-1-/-Ldlr-/- mice than in Ldlr-/-, both on a low 
fat diet (p <0.002) and following a high fat diet  (p <0.001).   
 
In summary, therefore, deficiency of DAF significantly enhanced complement 
activation in Ldlr-/- mice, as judged both by C3d and C5b-9 deposition, and this was 
associated with increased atherosclerotic lesion formation.  
 
DISCUSSION   
This study provides the first experimental evidence showing the importance of C3 
regulation by DAF in protection from atherosclerosis. Thus, DAF deficiency led to an 
increase in lipid deposition in the aorta and an acceleration of lesion formation and 
VSMC content in the aortic root.  As in our previous studies with C1q and CD59 
deficiencies, these changes were most marked in mice fed a low fat diet (24;41). 
Taking the three studies together, the data are consistent with a homeostatic role for 
the classical complement pathway in the arterial wall on a low fat diet, which is 
overridden by the greater inflammatory milieu caused by high fat feeding.  
 
The results of this study need to be seen alongside the previous failure to observe an 
effect of DAF deficiency on ApoE-/- mice (40). It should be noted that the Ldlr-/- and 
ApoE-/- mouse models are not totally interchangeable, with atherosclerosis in ApoE-/- 
being less dependent upon diet (46). This may possibly have obscured seeing 
differences that in daf-1-/-Ldlr-/- mice were most prominent on the low fat diet. Other 
factors that may have prevented observing a phenotype in daf-1-/-ApoE-/- mice include 
confounding effects of ApoE deficiency on macrophage and T lymphocyte function 
(47;48).  A further consideration is that our study of daf-1-/-Ldlr-/- mice was restricted 
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to female mice to reduce experimental variability. As male Ldlr-/- mice tend to have 
more severe disease (49), we do not yet know whether there are gender differences in 
the effects we have observed.  
 
A central part of this study has been the validation of the use of an anti-C3d antibody 
for analysis of C3 activation in mouse tissues. This antibody recognises C3d but not 
intact C3 or C3b, the latter evident from the lack of staining of C3 or C3b in the 
glomeruli of Factor I deficient mice. We have not specifically examined reactivity of 
this antibody with iC3b. However, since this C3d-reactive antibody did not recognise 
native C3, we used it as a marker of C3 activation. Using this antibody, we found that 
there was detectable C3 activation in the aortic root lesions of Ldlr-/- mice fed a low 
fat diet, and that this was markedly increased in the absence of DAF. Although DAF 
is primarily considered a cell surface protein, it is also found in soluble form, and this 
perhaps accounts for the increase in C3d in acellular as well as cellular regions of daf-
1-/-Ldlr-/- lesions (50). Although high fat feeding increased C3 activation in DAF 
deficient mice, no such effect was seen in Ldlr-/- single knock-outs, suggesting that 
DAF normally provides a robust control of C3 activation in response to 
hyperlipidaemia. It is worth noting that the intensity of C3 staining also increased 
with high fat feeding, suggesting a positive feedback loop whereby increased 
availability of C3 in the inflamed arterial wall (for example via local synthesis (51)) 
may increase C3 activation in the absence of DAF.  
 
We also found that DAF deficiency leads to an obvious increase in C5b-9 deposition 
in the aortic root, both on the low fat and high fat diets.  We interpret this observation 
as indicating the central importance of C3 in complement regulation and showing that 
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increased terminal pathway activation in DAF deficient mice is sufficient to 
overwhelm the inhibitory capacity of CD59.  In general, the phenotype of daf-1-/-Ldlr-
/- 
 mice was similar to that which we have previously reported for mice lacking CD59, 
apart from a greater prominence of VSMC in the aortic root lesions of high fat diet 
fed mice in the latter (41). The cause for this is not clear, but could relate to the 
capacity of CD59 to protect VSMC from the established pro-proliferative signalling 
effects of C5b-9 (2;52).  In this respect it is notable that VSMC showed only low level 
DAF expression, in contrast to a high level of CD59 expression seen previously (41).    
 
The mechanisms responsible for the increase in atherosclerosis in DAF deficient 
animals are likely at least in part to reflect increased C3 activation, and to include an 
increase in the recruitment and activation of monocytes via anaphylatoxins (C3a and 
C5a), and the effects on cell activation and proliferation of C5b-9 (2;53).  Clearly an 
increased recruitment of monocytes could also be expected to amplify inflammation 
through release of cytokines and other inflammatory mediators, but this has not been 
investigated further. Although we have failed to demonstrate a reduction in C3 serum 
in daf-1-/-Ldlr-/-  mice (not shown), it is also possible that increased systemic 
complement activation may play a role.  We are not aware of any interaction between 
DAF and the LDL receptor, but DAF does have other reported actions that might 
possibly have contributed to the effects we have observed, including acting as a signal 
transduction  receptor on monocytes and T lymphocytes and influencing leukocyte 
adhesion (54-59).  
 
DAF and CD59 are just two of several regulators of complement activity, and 
establishing the relative roles in this model of other fluid phase (eg Factor H (60)) and 
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membrane-bound complement regulators now deserves further study, particularly 
with respect to their relative importance on different cell types (ie macrophages vs 
VSMC).  In this context, it should be noted that there is an additional membrane 
bound inhibitor of C3 activity in the mouse, designated Complement Receptor 1 
(CR1)-related gene y (Crry) (61). In view of the clear non-redundant role of DAF 
demonstrated by our data, determining the relative contributions of DAF and Crry in 
arterial homeostasis will be of great interest. Further studies will also be needed 
delineate the effects of agents found to be protective in other arterial disease models, 
such as C1 esterase inhibitor (62). 
 
Expression of complement proteins and complement regulators has been well 
documented in human atherosclerosis, underscoring the importance of understanding 
the details of complement biology in the arterial wall via analysis of mouse models 
(63). DAF is not expressed on normal VSMC but can be identified on VSMC as well 
as macrophages in advanced plaques, and is functionally competent as a complement 
regulator ex vivo (64;65). Furthermore, mRNA transcripts for DAF and other 
complement regulators appear to be proportionately less in plaques than those for 
complement pathway proteins (51). This imbalance may be particularly important in 
allowing complement activation, in view of the limited capacity of the soluble 
regulator Factor H to penetrate into atherosclerotic lesions (60). 
 
In conclusion, we have presented data showing that DAF plays a central role in the 
regulation of complement activation in the arterial wall in mice, consistent with the 
emerging paradigm in which the proximal classical complement pathway has a 
critical homeostatic protective effect while distal complement activity is atherogenic.  
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TABLE 
 
Body weights and total serum cholesterol and triglycerides in 
 22 week old Ldlr-/- and daf-1-/-Ldlr-/- mice 
 
 
 
 
 
 
 
 
Ldlr-/- 
 
daf-1-/-Ldlr-/- 
 
 
mean + SEM   
 
mean +SEM   
Low fat diet 
Number 
 
23 
 
22 
Final body weight (g) 25.13   +   0.68   23.90  +  0.41  
Total cholesterol (mmol/l) 9.44   +   1.58  9.21  +  2.15  
Triglyceride (mmol/l) 1.76   +   0.54  1.78  +  0.46  
   
High fat diet 
Number 
 
18 
 
17 
Final body weight (g) 25.22  +  0.73  26.91   +   0.45  
Total cholesterol (mmol/l) 23.04  +  3.07  21.88   +   5.33  
Triglyceride (mmol/l) 3.26 +  0.73  3.36   +   0.55 
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FIGURE LEGENDS 
Figure 1.  DAF deficiency accelerates aortic lipid deposition:  (A-D) 22 weeks old 
mice fed a low fat (A,B) or a high fat (C,D) diet from the age of 12 weeks. Mice were 
perfused in vivo with Sudan IV, after which aortae were excised and processed for en 
face staining as described in Methods. (A,C) Ldlr-/-, (B,D) daf-1-/-Ldlr-/-. Scale bar 
represents 1cm; (E) Comparison of lesion areas following image analysis of en face 
staining. Values are group means + SEM.    
 
Figure 2: DAF deficiency accelerates atherosclerotic lesion development in the aortic 
root: (A-D) photomicrographs of aortic roots in 22 weeks old mice stained with Oil 
Red O and counterstained with haematoxylin following (A,B) low fat diet or (C,D) 
high fat diet from aged 12 weeks. (A, C)  Ldlr-/-, (B,D) daf-1-/-Ldlr-/-. Scale bars 
represent 1 mm; (E) Comparison of lesion areas in Ldlr-/- and daf-1-/-Ldlr-/-mice, 
expressed as a percentage fraction of the aortic root area.  Values are group means + 
SEM.     
 
Figure 3. Increased alpha-actin staining reveals increased lesion complexity in Daf -/-
Ldlr -/- mice fed a low fat diet:  The photomicrographs are representative section 
images of aortic root lesions from (A,C) Ldlr-/- and (B,D) daf-1-/-Ldlr-/- mice fed (A,B) 
a low fat or (C,D) high fat diet, with VSMC stained with Cy3-conjugated anti-alpha 
actin (red). Nuclei are stained with TOPRO (far red and near infra-red original, blue 
pseudocoloured for visualisation). L = lumen; Scale bars represent 50mm.  
Quantification of (E) alpha actin staining and (F) macrophages identified by mAb 
MOMA-2, both expressed as percentage of lesional cells. The histogram shows a 
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significant increase in VSMC in DAF deficient mice fed a low fat diet. Values are 
group means + SEM.   
 
Figure 4. Confocal microscopy showing localization of DAF in relation to endothelial 
cells, macrophages and VSMC: Aortic root sections from high fat-fed Ldlr-/- mice 
were analysed by confocal microscopy to detect the presence of DAF on endothelial 
cells, macrophages and VSMC.  (A) Rat anti-mouse DAF (clone MD1), followed by 
biotinylated polyclonal rabbit anti-rat secondary and development with AlexaFluor® 
568-conjugated streptavidin (pseudocoloured green), filled green arrowhead shows 
strong DAF expression in non-lesional area, whereas open green arrowhead shows 
weak DAF expression in lesional area; (B)  AlexaFluor® 488-conjugated anti-CD31 
reacting with endothelial cells (pseudocoloured red),  filled red arrowhead shows 
maintained CD31 staining over lesion; (C) TOPRO-3 nuclear dye (pseudocoloured 
blue) and (D) merged image of (A), (B) and (C) where filled yellow arrowhead points 
to colocalisation of CD31 and DAF over non-lesional area (yellow overlay = 
red/green combined), and open red arrowhead points to positive CD31 (red) but weak 
DAF (green) expression over lesion;  (E) rat anti-mouse DAF (clone MD1), followed 
by biotinylated polyclonal rabbit anti-rat secondary and development with 
AlexaFluor® 488-conjugated streptavidin (green), filled green arrows point to DAF 
expression in plaque and in adventitia;  (F) AlexaFluor® 568-labelled anti-CD68 
(macrophages, red), with filled red arrows showing CD68 expression by plaque and 
adventitia macrophages; (G) TOPRO-3 as in (C); (H) merged image of (E), (F) and 
(G), where filled yellow arrows point to colocalisation of  CD68 and DAF in some 
macrophages (yellow = red / green combined), both in the superficial plaque and in 
adventitia;  (I) DAF staining as in (E), filled green arrowheads show DAF expression 
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in intima and adventitia (J) Cy3-conjugated anti-alpha actin to identify VSMC (red); 
(K) TOPRO-3 as in (C), and (L) merged image of (I), (J) and (K), where open block 
arrow shows little DAF colocalization with VSMC  (if present, would be yellow = 
red/green combined). Scale bars represent 50µm.  L= lumen. 
 
Figure 5. Validation of polyclonal anti-C3d antibody for detecting activated C3: (A) 
ELISAs to detect C3 and C3d in sera from wild-type mice, factor I-deficient mice and 
sera from wild-type mice incubated with trypsin in vitro.  Y axis represents optical 
density (OD) readings. The result is representative of two experiments; (B-E) Using a 
polyclonal anti-C3 antibody, mesangial C3 staining is readily evident in the glomeruli 
of kidney sections from factor I-deficient mice (B). No staining is seen when an anti-
C3d antibody is used (C) demonstrating that the anti-C3d antibody does not react with 
C3 in tissue. Following incubation of the sections with a source of murine factor I, 
mesangial C3 reactivity becomes apparent using both the anti-C3 (D) and anti-C3d 
antibody (E).  
 
Figure 6.  DAF deficiency significantly increases C3d deposition in atherosclerotic 
lesions: Histograms showing percentage of lesion positive for C3 (A) and C3d (C), 
and intensity of positive C3 (B) and C3d (D) staining, where values are means + 
SEM;   (E-J) Photomicrographs of aortic root lesions of Ldlr-/- (E,G) and daf-1-/-Ldlr-
/-
 (F,H) following a low fat (E, F) or high fat (G,H) diet were stained for confocal 
microscopy to visualise C3d; (I,J) corresponding IgG controls on section of low fat 
(I) and high fat (J) diet fed mouse; (K,L) show absence of anti-C3d staining of aortic 
root sections of 22 week old low fat (K) and high fat (L) diet high fed C3 deficient 
Ldlr-/- mice. Numbers studied were 16 Ldlr-/-  and 11 daf-1-/-Ldlr-/- on low fat, and 15 -/- 
Ldlr-/- and 8 daf-1-/-Ldlr-/- on high fat. Scale bars = 50µm. 
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Figure 7.   DAF deficiency significantly increases C5b-9 deposition in atherosclerotic 
lesions:  Representatives photomicrographs of aortic root sections of (A) a low fat fed  
Ldlr-/- mouse stained with control rabbit IgG (score 0),  (B) a low fat fed Ldlr-/- mouse 
(score +) stained with anti-C5b-9, and (C) a low fat fed daf-1-/-Ldlr-/- mouse (score 
+++) stained with anti-C5b-9 (score +++). Scale bars represent 100µm; L = lumen.  
(D) shows a the summary of semiquantitative scoring. Statistical analysis was 
performed with Mann-Whitney test. 
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